Free webinar: Innovation-driven responses to the COVID-19 crisis
Event time and date: Tuesday September 29th, 9:00 – 10:30 CEST.
Hosts: The Royal Danish Embassy in Tokyo and Healthcare DENMARK
The COVID-19 pandemic has placed an urgent demand on vaccine development and a deep understanding the immune response to SARS-CoV-2. Immunitrack is committed to playing its role in the fight against COVID-19 by leveraging its in vitro epitope prediction technology to support vaccine development and immune monitoring in infected and recovered COVID-19 patients.
Mapping T cell epitopes in SARS-CoV-2 for vaccine development and immune monitoring in infected and recovered patients
On the 29th September, Immunitrack will present its company response and innovative technological contributions to fighting the COVID-19 pandemic for an audience of academics, industrial stakeholders, policy makers and other interested parties in Japan. The presentation will be given by Immunitrack’s CEO Dr. Stephan Thorgrimsen as a free live online webinar hosted by the Royal Danish Embassy in Tokyo and Healthcare DENMARK.
Registration and Event Details
Registration for the event is free and you can do so here ▸
You will find more information about the event programme here ▸
Immunitrack is founded upon world-leading academic research on MHC-epitope binding. Using our deep knowledge in this area, we have developed the proprietary epitope screening platform technology, NeoScreen®. NeoScreen® accurately assays the affinity and stability of MHC/epitope interactions, and the technology has the capacity to rapidly screen libraries with thousands of (neo-) epitopes for applications within immune-oncology, vaccine production, T cell therapies and immune monitoring.